vimarsana.com

Latest Breaking News On - Benjamin philip levy - Page 1 : vimarsana.com

Dr Levy on the Evolution of ADCs in NSCLC

Benjamin Philip Levy, MD, discusses the evolution of antibody-drug conjugates in non-small cell lung cancer following updated data to be read out for this treatment population throughout 2023.

Emerging TROP-2 Directed ADCs Show Promise in Advanced NSCLC

Dr Levy on the Ongoing Development of TROP-2 ADCs in NSCLC

Benjamin Philip Levy, MD, discusses the ongoing development of the TROP-2 directed antibody-drug conjugates sacituzumab govitecan-hziy and datopotamab deruxtecan in non–small cell lung cancer, their different toxicity profiles, as well as the potential categorization of emerging ADCs as onco-directed therapies in this patient population.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.